About US
Contact us
-
Biohaven lines up rhinosinusitis patients for trial of its migraine med Nurtec ODTEven in a crowded field full of formidable competitors, Biohaven has set itself apart with migraine medication Nurtec ODT just two years after it was approved. Now the company has another2022/2/22
-
ASCO GU: J&J plays up precision therapy approach for Zejula's prostate cancer bid after mixed resultsIn 2017 and 2020, Zejula snagged broad FDA labels for ovarian cancer patients who responded well to a chemotherapy. But in prostate cancer, the PARP inhibitor appears to work only for a niche populat2022/2/16
-
ASCO GU: AstraZeneca, Merck’s Lynparza one-ups J&J’s Zejula with prostate cancer win regardless of gene mutationsAstraZeneca and Merck & Co.’s Lynparza may have a narrower label than GlaxoSmithKline’s rival drug Zejula in ovarian cancer, but in prostate cancer, the situation could flip. Adding L2022/2/16
-
After Califf survives narrow Senate vote, FDA nominee looks set to be confirmed this weekStanding alongside a poster of a young constituent, former West Virginia University cheerleader Lauren Cole, who died of an opiate overdose, West Virginia Senator Joe Manchinexplainedwhy he opposed t2022/2/14
-
National Resilience snares Takeda plasma development and manufacturing dealManufacturing newcomer National Resilience, already working on Moderna’s COVID-19 vaccine in Canada, has enlisted another high-profile client. Resilience has clinched a deal tochip inon development a2022/2/14
-
AstraZeneca R&D chiefs talk roxadustat trial, Ultomiris threats and Imfinzi wingman treme’s futureAstraZeneca’s R&D expense swelled 59% in 2021 to nearly $10 billion. The acquisition of Alexion contributed some, and a mid-stage cull related to the buyout of Ardea Biosciences also cost the com2022/2/11
-
Teva CEO says company could pay up to $3.6B to put opioid litigation to bed: reportTeva could shell out as much as $3.6 billion in cash and meds to settle thousands of opioid lawsuits, Reuters reports. CEO Kåre Schultztoldthe news outlet Teva would likely pay $2.7 billion to $3.6 b2022/2/11
-
Bayer poaches GlaxoSmithKline exec to lead expanding oncology business—including a blockbuster hopefulOncology is hardly what Bayer is known for. But the German drugmaker has raided GlaxoSmithKline—which is itself reestablishing a cancer foothold—for a new leader in the field. Christine R2022/2/8
-
FDA probes TG Therapeutics' Ukoniq over potential for elevated death risks 1 year after drug's approvalHyped as a safer version of other drugs in its class upon its approval last February, TG Therapeutics’ Ukoniqappearedon its way to differentiating itself in certain types of lymphoma. But a year late2022/2/8
-
Novo Nordisk's Wegovy, hamstrung by Catalent FDA write-up, could correct course by mid-2022: analystsWorry not, Wegovy fans: There’s reason to believe supply of Novo Nordisk’s obesity med could resume as planned by the middle of the year. That’s according to Jefferies analysts’ chat with a manufactu2022/1/29